New pill targets leukemia in early human trial
NCT ID NCT05918692
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental pill called BMF-500 in 35 adults with acute leukemia, especially those with a specific genetic mutation (FLT3). The main goals are to check the drug's safety, find the right dose, and see if it can help control the disease. Participants must have leukemia that has come back or not improved after prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BMF-500 (an oral FLT3 inhibitor)
What this could lead to
If successful, this could lead to a new targeted treatment option for patients with acute leukemia that has returned or not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 35 participants, so it is primarily testing safety and dosing. The drug may not prove effective or could have significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
Texas Oncology-PA USOR
Dallas, Texas, 75251, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Kentucky - Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
Virginia Cancer Specialists
Gainesville, Virginia, 20155, United States
-
Winship Cancer Institute, Emory University
Atlanta, Georgia, 30322, United States